Loading
Life sciences · Review
Food Production Processing and Nutrition · October 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Magnesium is an essential cofactor in numerous enzymatic reactions regulating neuronal excitability, neurotransmission, and stress response. Deficiency has been linked to affective dysregulation through altered N-methyl-D-aspartate (NMDA) and γ-aminobutyric acid (GABA) signaling, impaired neuroplasticity, and activation of the hypothalamic–pituitary–adrenal (HPA) axis (Murck, 2002; Singewald et al., 2004; Poleszak et al., 2004; see Appendix C for detailed preclinical evidence). This systematic review aims to synthesize clinical and epidemiological evidence on magnesium and affective disorders, summarizing preclinical findings separately as mechanistic background. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, a systematic search of PubMed, Scopus, Embase, and PsycINFO (January 2000–June 2026) identified 21 eligible human studies (9 randomized controlled trials [RCTs], 8 observational, 4 systematic reviews or meta-analyses). Preclinical and mechanistic studies ( n = 14) were reviewed separately in the Supplementary Material and were not part of the systematic synthesis. Because of substantial heterogeneity, no new meta-analysis was conducted; a structured narrative synthesis integrated quantitative estimates from existing trials and meta-analyses. Across clinical studies, magnesium supplementation was associated with reductions in depressive and anxiety symptoms, especially in individuals with low magnesium or partial antidepressant response. Combination regimens with vitamin B6 or D improved stress resilience and quality of life. Evidence quality ranged from moderate to high, though differences in dosage, formulation, and population limited comparability. Magnesium supplementation shows preliminary evidence of efficacy as an adjunctive treatment for mood and anxiety symptoms, with moderate certainty for depression and low-to-moderate certainty for anxiety. While preclinical data support biological plausibility, mechanistic validation in human trials remains limited. Large, biomarker-guided randomized trials are needed to confirm efficacy and define optimal dosing within precision psychiatry.